Brief: Basilea Announces That FDA Approves Expanded Use Of Antifungal Cresemba® (Isavuconazole) In The United States In Children With Invasive Aspergillosis And Invasive Mucormycosis

Basilea Pharmaceutica AG, Allschwil

11/12/2023 06:18

Dec 11 (Reuters) - Basilea Pharmaceutica AG Allschwil
 BSLN.S :
    * BASILEA ANNOUNCES THAT FDA APPROVES EXPANDED USE OF
ANTIFUNGAL
CRESEMBA® (ISAVUCONAZOLE) IN THE UNITED STATES IN CHILDREN WITH
INVASIVE ASPERGILLOSIS AND INVASIVE MUCORMYCOSIS
    * BASILEA - FDA GRANTED PEDIATRIC EXCLUSIVITY FOR CRESEMBA,
WHICH
EXTENDS PERIOD OF MARKET EXCLUSIVITY IN UNITED STATES  TO
SEPTEMBER 2027

Source text for Eikon:  ID:nGNX6CXRT6 
Further company coverage:  BSLN.S 

 ((Reuters.Briefs@thomsonreuters.com;))